Sagard Healthcare Partners
Sagard Healthcare Partners
Sagard Healthcare Partners invests in royalties and credit backed by approved and commercialized biopharmaceutical products, diagnostics and medical devices. We aim to accelerate the returns on innovation for owners of intellectual property while offering investors an attractive healthcare exposure largely uncorrelated to other asset classes. Sagard Healthcare Partners is led by a team that has worked together for over a decade.
Sagard Healthcare invests in royalties and credit backed by approved and commercialized biopharmaceutical products, diagnostics and medical devices. We aim to accelerate the returns on innovation for owners of intellectual property while offering investors an attractive healthcare exposure largely uncorrelated to other asset classes. Sagard Healthcare is led by a team that has worked together for over a decade.
Investment approach and value proposition
Our differentiation
- We are a proven team of industry experts with deep experience in a complex investment strategy and a history of working together
- We have a flexible mandate including royalty monetization, revenue-interest financing and traditional credit to match the right type of investment to each opportunity, and direct capital to areas of higher relative value
- Our focus on the long-term enables value maximization for both sides in a transaction
- As part of the Sagard platform, we have access to strong operational infrastructure, business support, and networks, enabling our team to focus on investments that accelerate returns on innovation in the healthcare industry
Our differentiation
- We are a proven team of industry experts with deep experience in a complex investment strategy and a history of working together
- We have a flexible mandate, including royalties and royalty-backed credit, to enable the deployment of capital to areas of higher relative value
- Our evergreen fund structure enables long-term ownership and value maximization
- As part of the Sagard platform, we have access to world-class operational infrastructure, business support and network, enabling our team to focus and accelerate scaling
Our differentiation
Our differentiation
- We are a proven team of industry experts with deep experience in a complex investment strategy and a history of working together
- We have a flexible mandate, including royalties and royalty-backed credit, to enable the deployment of capital to areas of higher relative value
- Our evergreen fund structure enables long-term ownership and value maximization
- As part of the Sagard platform, we have access to world-class operational infrastructure, business support and network, enabling our team to focus and accelerate scaling
Our differentiation
- We are a proven team of industry experts with deep experience in a complex investment strategy and a history of working together
- We have a flexible mandate, including royalties and royalty-backed credit, to enable the deployment of capital to areas of higher relative value
- Our evergreen fund structure enables long-term ownership and value maximization
- As part of the Sagard platform, we have access to world-class operational infrastructure, business support and network, enabling our team to focus and accelerate scaling
Our differentiation
- We are a proven team of industry experts with deep experience in a complex investment strategy and a history of working together
- We have a flexible mandate, including royalties and royalty-backed credit, to enable the deployment of capital to areas of higher relative value
- Our evergreen fund structure enables long-term ownership and value maximization
- As part of the Sagard platform, we have access to world-class operational infrastructure, business support and network, enabling our team to focus and accelerate scaling
Our differentiation
- We are a proven team of industry experts with deep experience in a complex investment strategy and a history of working together
- We have a flexible mandate, including royalties and royalty-backed credit, to enable the deployment of capital to areas of higher relative value
- Our evergreen fund structure enables long-term ownership and value maximization
- As part of the Sagard platform, we have access to world-class operational infrastructure, business support and network, enabling our team to focus and accelerate scaling
Our differentiation
- We are a proven team of industry experts with deep experience in a complex investment strategy and a history of working together
- We have a flexible mandate, including royalties and royalty-backed credit, to enable the deployment of capital to areas of higher relative value
- Our evergreen fund structure enables long-term ownership and value maximization
- As part of the Sagard platform, we have access to world-class operational infrastructure, business support and network, enabling our team to focus and accelerate scaling
Investment criteria
- We acquire royalties, provide royalty-backed loans and invest directly in approved biopharmaceuticals, diagnostics and medical devices in return for a royalty on direct sales
- Typical investment size between $25M and $150M
- We can do smaller transactions to support innovative emerging companies
- Through our LP co-investment program, we can do larger deals in the hundreds of millions
Investment criteria
- Biopharmaceutical royalties, royalty securitizations, and structured credit investments globally
- Investment size between US$5-100 million
Investment criteria
- We acquire royalties, provide royalty-backed loans, and invest directly in approved biopharmaceuticals, diagnostics, and medical devices in return for a royalty on direct sales
- Typical investment size between US$25M to US$150M
- We can do smaller transactions to support innovative emerging companies
- Through our LP co-investment program, we can do larger deals in the hundreds of millions
Investment criteria
- Biopharmaceutical royalties, royalty securitizations, and structured credit investments globally
- Investment size between US$5-100 million
Investment criteria
- We acquire royalties, provide royalty-backed loans, and invest directly in approved biopharmaceuticals, diagnostics, and medical devices in return for a royalty on direct sales
- Typical investment size between US$25M to US$150M
- We can do smaller transactions to support innovative emerging companiesThrough our LP co-investment program, we can do larger deals in the hundreds of millions
Investment criteria
- Biopharmaceutical royalties, royalty securitizations, and structured credit investments globally
- Investment size between US$5-100 million
Investment criteria
- We acquire royalties, provide royalty-backed loans, and invest directly in approved biopharmaceuticals, diagnostics, and medical devices in return for a royalty on direct sales
- Typical investment size between US$25M to US$150M
- We can do smaller transactions to support innovative emerging companies
- Through our LP co-investment program, we can do larger deals in the hundreds of millions
Investment criteria
- Biopharmaceutical royalties, royalty securitizations, and structured credit investments globally
- Investment size between US$5-100 million
Investment criteria
- We acquire royalties, provide royalty-backed loans, and invest directly in approved biopharmaceuticals, diagnostics, and medical devices in return for a royalty on direct sales
- Typical investment size between US$25M to US$150M
- We can do smaller transactions to support innovative emerging companies
- Through our LP co-investment program, we can do larger deals in the hundreds of millions
Investment criteria
- Biopharmaceutical royalties, royalty securitizations, and structured credit investments globally
- Investment size between US$5-100 million
Investment criteria
- We acquire royalties, provide royalty-backed loans, and invest directly in approved biopharmaceuticals, diagnostics, and medical devices in return for a royalty on direct sales
- Typical investment size between US$25M to US$150MWe can do smaller transactions to support innovative emerging companies
- Through our LP co-investment program, we can do larger deals in the hundreds of millions
Investment criteria
- Biopharmaceutical royalties, royalty securitizations, and structured credit investments globally
- Investment size between US$5-100 million
Investment criteria
- We acquire royalties, provide royalty-backed loans, and invest directly in approved biopharmaceuticals, diagnostics, and medical devices in return for a royalty on direct sales
- Typical investment size between US$25M to US$150M
- We can do smaller transactions to support innovative emerging companies
- Through our LP co-investment program, we can do larger deals in the hundreds of millions
Investment criteria
- Biopharmaceutical royalties, royalty securitizations, and structured credit investments globally
- Investment size between US$5-100 million
Investment criteria
- We acquire royalties, provide royalty-backed loans, and invest directly in approved biopharmaceuticals, diagnostics, and medical devices in return for a royalty on direct salesTypical investment size between US$25M to US$150M
- We can do smaller transactions to support innovative emerging companies
- Through our LP co-investment program, we can do larger deals in the hundreds of millions
Investment criteria
- Biopharmaceutical royalties, royalty securitizations, and structured credit investments globally
- Investment size between US$5-100 million
Investment criteria
- We acquire royalties, provide royalty-backed loans, and invest directly in approved biopharmaceuticals, diagnostics, and medical devices in return for a royalty on direct sales
- Typical investment size between US$25M to US$150M
- We can do smaller transactions to support innovative emerging companies
- Through our LP co-investment program, we can do larger deals in the hundreds of millions
Investment criteria
- Biopharmaceutical royalties, royalty securitizations, and structured credit investments globally
- Investment size between US$5-100 million
Investment criteria
- We acquire royalties, provide royalty-backed loans, and invest directly in approved biopharmaceuticals, diagnostics, and medical devices in return for a royalty on direct sales
- Typical investment size between US$25M to US$150M
- We can do smaller transactions to support innovative emerging companies
- Through our LP co-investment program, we can do larger deals in the hundreds of millions
Investment criteria
- Biopharmaceutical royalties, royalty securitizations, and structured credit investments globally
- Investment size between US$5-100 million
Investment criteria
- We acquire royalties, provide royalty-backed loans, and invest directly in approved biopharmaceuticals, diagnostics, and medical devices in return for a royalty on direct sales
- Typical investment size between US$25M to US$150M
- We can do smaller transactions to support innovative emerging companies
- Through our LP co-investment program, we can do larger deals in the hundreds of millions
Investment criteria
- Biopharmaceutical royalties, royalty securitizations, and structured credit investments globally
- Investment size between US$5-100 million
Investment criteria
Investment criteria
- Biopharmaceutical royalties, royalty securitizations, and structured credit investments globally
- Investment size between US$5-100 million
Investment criteria
Investment criteria
- Biopharmaceutical royalties, royalty securitizations, and structured credit investments globally
- Investment size between US$5-100 million
Investment criteria
- Biopharmaceutical royalties, royalty securitizations, and structured credit investments globally
- Investment size between US$5-100 million
Investment criteria
- Biopharmaceutical royalties, royalty securitizations, and structured credit investments globally
- Investment size between US$5-100 million
Our portfolio companies
We partner with ambitious companies to help them achieve their aspirations.
See all companies
Connect with us
